Talotrexin

DRACPC ID  DRACPC0074

Active Ingredients   Talotrexin

Description  An antimetabolite analogue of aminopterin with potential antineoplastic activity. As a folate antagonist, talotrexin binds to and inhibits the function of dihydrofolate reductase, resulting in the inhibition of folate metabolism, DNA synthesis, and cell division. Hydrosoluble, talotrexin is actively transported into cells by the reduced folate carrier (RFC) and, therefore, is unlikely to be associated with P-glycoprotein-mediated multidrug resistance.

Synonyms  PT523; N(alpha)-(4-Amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine; Talopterin; Talotrexin

Type  Small Molecule

Disease  Lung cancer, Leukemia

Classification

  

Folate antagonist Peptide and derivative

Structure Information


Molecular Formula  C27H27N9O6

Molecular Weight  573.6

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  2-[[(4S)-4-carboxy-4-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]butyl]carbamoyl]benzoic acid

InChI  InChI=1S/C27H27N9O6/c28-21-20-22(36-27(29)35-21)32-13-16(33-20)12-31-15-9-7-14(8-10-15)23(37)34-19(26(41)42)6-3-11-30-24(38)17-4-1-2-5-18(17)25(39)40/h1-2,4-5,7-10,13,19,31H,3,6,11-12H2,(H,30,38)(H,34,37)(H,39,40)(H,41,42)(H4,28,29,32,35,36)

InChI_Key NYQPLPNEESYGNO-UHFFFAOYSA-N

SMILES  NC1=NC(N)=C2N=C(C=NC2=N1)CNC3=CC=C(C=C3)C(NC(C(O)=O)CCCNC(C4=C(C=CC=C4)C(O)=O)=O)=O

External Codes


PubChem CID  130731

DrugBank Accession Number  DB06178

NCI Thesaurus Code  C29341  

UNII  A8E516A20K   GSRS

CAS  113857-87-7



Drug approval


Drug indication
    Investigated for use/treatment in solid tumors, lung cancer, leukemia (unspecified), and leukemia (lymphoid).

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00458744 A Phase I Study Of Talotrexin (PT-523) In Children And Adolescents With Recurrent Solid Tumors Or Recurrent/Refractory Leukemias Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific Phase 1 Treatment
NCT00098514 A Phase I Study Of PT523 In Patients With Solid Tumors Unspecified Adult Solid Tumor, Protocol Specific Phase 1 Treatment
NCT00112060 A Phase I/II, Open-Label, Multicenter Study of Single Agent PT-523 in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) Non-Small-Cell Lung Carcinoma Phase 1/2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.